Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

Intervening in Diabetes With Healthy Eating, Activity, and Linkages To Healthcare - The I-D-HEALTH Study
Community Translation of a Lifestyle Intervention to Improve Health in Diabetes
Status: Enrolling
Updated:  3/27/2018
McGaw YMCA
mi
from
Evanston, IL
Intervening in Diabetes With Healthy Eating, Activity, and Linkages To Healthcare - The I-D-HEALTH Study
Community Translation of a Lifestyle Intervention to Improve Health in Diabetes
Status: Enrolling
Updated: 3/27/2018
McGaw YMCA
mi
from
Evanston, IL
Click here to add this to my saved trials
Effect of Harvoni on Proteinuria and Estimated Glomerular Filtration Rate (eGFR) in Hepatitis C (HCV) Associated Chronic Kidney Disease (CKD)
Effect of Ledipasvir and Sofosbuvir on Proteinuria and Estimated Glomerular Filtration Rate in Patients With Early Stage (1-3) Hepatitis C Associated Chronic Kidney Disease
Status: Enrolling
Updated:  3/28/2018
Massachusetts General Hospital
mi
from
Boston, MA
Effect of Harvoni on Proteinuria and Estimated Glomerular Filtration Rate (eGFR) in Hepatitis C (HCV) Associated Chronic Kidney Disease (CKD)
Effect of Ledipasvir and Sofosbuvir on Proteinuria and Estimated Glomerular Filtration Rate in Patients With Early Stage (1-3) Hepatitis C Associated Chronic Kidney Disease
Status: Enrolling
Updated: 3/28/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Dichotic Listening as a Predictor of Medication Response in Depression
Dichotic Listening as a Predictor of Medication Response in Depression
Status: Enrolling
Updated:  3/29/2018
New York State Psychiatric Institute
mi
from
New York, NY
Dichotic Listening as a Predictor of Medication Response in Depression
Dichotic Listening as a Predictor of Medication Response in Depression
Status: Enrolling
Updated: 3/29/2018
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers
A Multiple Dose, Pharmacokinetic Study Comparing Different Regimens of Testosterone Given as Intranasal NASOBOL® in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers
Status: Enrolling
Updated:  3/29/2018
Harbor UCLA Medical Center
mi
from
Torrance, CA
NASOBOL in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers
A Multiple Dose, Pharmacokinetic Study Comparing Different Regimens of Testosterone Given as Intranasal NASOBOL® in Hypogonadal Men in Comparison to Testosterone Levels in Normal Healthy Male Volunteers
Status: Enrolling
Updated: 3/29/2018
Harbor UCLA Medical Center
mi
from
Torrance, CA
Click here to add this to my saved trials
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
Status: Enrolling
Updated:  3/29/2018
Hospital for Special Surgery
mi
from
New York, NY
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
Status: Enrolling
Updated: 3/29/2018
Hospital for Special Surgery
mi
from
New York, NY
Click here to add this to my saved trials
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
Status: Enrolling
Updated:  3/29/2018
Division of Rheumatology, University of Texas Medical Branch
mi
from
Galveston, TX
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
Status: Enrolling
Updated: 3/29/2018
Division of Rheumatology, University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
Nutrition, Inflammation and Insulin Resistance in End-Stage Renal Disease
Status: Enrolling
Updated:  3/29/2018
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
mi
from
Nashville, TN
Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
Nutrition, Inflammation and Insulin Resistance in End-Stage Renal Disease
Status: Enrolling
Updated: 3/29/2018
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
mi
from
Nashville, TN
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Birmingham, AL
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Mobile, AL
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Tucson, AZ
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
San Diego, CA
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Aventura, FL
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Aventura, FL
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Brandon, FL
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Brandon, FL
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Jacksonville, FL
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Shreveport, LA
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Elkridge, MD
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Elkridge, MD
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Garden City, NY
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Garden City, NY
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
New York, NY
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Columbus, OH
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Franklin, OH
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Franklin, OH
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Medford, OR
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Medford, OR
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Charleston, SC
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Greer, SC
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Greer, SC
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Hurst, TX
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Hurst, TX
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
West Valley City, UT
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
West Valley City, UT
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Olympia, WA
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Olympia, WA
Click here to add this to my saved trials
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated:  3/29/2018
Clinical Research Facility
mi
from
Renton, WA
Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism
A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism
Status: Enrolling
Updated: 3/29/2018
Clinical Research Facility
mi
from
Renton, WA
Click here to add this to my saved trials
Vascular Risk After Kidney Transplantation
Vascular Risk After Kidney Transplantation
Status: Enrolling
Updated:  3/29/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Vascular Risk After Kidney Transplantation
Vascular Risk After Kidney Transplantation
Status: Enrolling
Updated: 3/29/2018
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Predicting Insulin Resistance in American Indian Youth
Predicting Insulin Resistance in American Indian Youth
Status: Enrolling
Updated:  3/29/2018
Rosebud Indian Reservation
mi
from
Rosebud, SD
Predicting Insulin Resistance in American Indian Youth
Predicting Insulin Resistance in American Indian Youth
Status: Enrolling
Updated: 3/29/2018
Rosebud Indian Reservation
mi
from
Rosebud, SD
Click here to add this to my saved trials
Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study
Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study
Status: Enrolling
Updated:  3/30/2018
University of Florida Department of Community Health and Family Medicine
mi
from
Gainesville, FL
Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study
Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study
Status: Enrolling
Updated: 3/30/2018
University of Florida Department of Community Health and Family Medicine
mi
from
Gainesville, FL
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated:  4/2/2018
University of Michigan
mi
from
Ann Arbor, MI
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated: 4/2/2018
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated:  4/2/2018
Oregon Health and Science University
mi
from
Portland, OR
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated: 4/2/2018
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated:  4/2/2018
University of Texas Southwestern Medical Center Division of Hematology/Oncolog
mi
from
Dallas, TX
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated: 4/2/2018
University of Texas Southwestern Medical Center Division of Hematology/Oncolog
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated:  4/2/2018
Swedish Neuroscience Institute 550 17th Avenue, Suite 500
mi
from
Seattle, WA
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated: 4/2/2018
Swedish Neuroscience Institute 550 17th Avenue, Suite 500
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated:  4/2/2018
Novartis Investigative Site
mi
from
Caba,
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status: Enrolling
Updated: 4/2/2018
Novartis Investigative Site
mi
from
Caba,
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Sacramento, CA
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Stanford, CA
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Stanford, CA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Jacksonville, FL
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Atlanta, GA
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Rochester, MN
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Reno, NV
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Reno, NV
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
New York, NY
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Chapel Hill, NC
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Durham, NC
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Bethlehem, PA
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Charleston, SC
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Chattanooga, TN
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Houston, TX
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Lubbock, TX
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Lubbock, TX
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated:  4/2/2018
Mallinckrodt Investigational Site
mi
from
Toronto,
Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)
Status: Enrolling
Updated: 4/2/2018
Mallinckrodt Investigational Site
mi
from
Toronto,
Click here to add this to my saved trials